The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.
Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.
A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.
Publications found:
8,553
Sort by:
Investigation Report on China Glucosamine Market, 2010-2019
US$ 2,000.00
... Glucosamine is of great demand in China. Most of the market share has been occupied by Shanxi Zhongyuanwei Pharmaceutical Co., Ltd, Bright Future Pharmaceutical Laboratories Limited, Rottapharm Ltd, Zhejiang Hisun Pharmaceutical Co., Ltd ...
June 2015
35 pages
Investigation Report on China Levothyroxine Market, 2010-2019
US$ 2,000.00
... Thyroid hormones (TH) have the greatest effect of promoting growth on five-month-old babies or younger ones. Without thyroid hormones ... Levothyroxine enjoys a vast demand in China. Merck (Germany), Berlin-Chemie AG (Germany) and China Associated Pharmaceutical all take up certain market share, among which Merck ...
June 2015
20 pages
Investigation Report on China Menotropins Market, 2010-2019
US$ 2,000.00
... Livzon Pharmaceutical, Livzon Pharmaceutical Group, Inc, Ferring Pharmaceytical Co., Ltd (Germany), Ma’anshan Fengyuan Pharmaceutical Co., Ltd, Yantai North Pharmaceutical Co., Ltd and Shanghai Livzon Pharmaceutical Co., Ltd, among which Shanghai Livzon Pharmaceutical Co., Ltd ...
June 2015
30 pages
Investigation Report on China Moxifloxacin Market, 2010-2019
US$ 2,000.00
... China are mainly produced by Nanjing Youke Pharmaceutical CO., Ltd and The Bayer Group whichowns the larger market share of over 95% for sales value in 2014. As an outstanding antibacterial drug, moxifloxacin ...
June 2015
20 pages
Investigation Report on China Ossotide Market, 2010-2019
US$ 2,000.00
... of rheumatoid arthritis (RA) is 0.2%-0.36% and the number of cases is 5-10 million in China. Apart from RA, osteoarthritis, an expression of ... ossotide in China competitive landscape of ossotide in Chinese market price of ossotide made by different enterprises in China market outlook of ossotide in China ...
June 2015
35 pages
Investigation Report on China Progesterone Market, 2010-2019
US$ 2,000.00
... progesterone in the Chinese market is imported and made by Fleet (UK) and Capsugel(FR). The rest mainly comes from such local manufacturers as Asen, Zhejiang Xianju Pharmaceutical Co., Ltd ... steroid drugs will keep growing and that with the development of downstream products, the demand for progesterone ...
June 2015
35 pages
Investigation Report on China Rosuvastatin Market, 2010-2019
US$ 2,000.00
... rosuvastatin (rosuvastatin calcium ... rosuvastatin in the Chinese market mainly come from the following companies: IPR Pharmaceuticals (US), Lunan Better Pharmaceutical Co., Ltd, Nanjing Chia Tai Tianqing, Simcere and Zhejiang Jingxin Pharmaceutical Co., Ltd, among which IPR Pharmaceuticals ...
June 2015
35 pages
Calming and Sleeping in Romania
US$ 990.00
Consumers in Romania have become increasingly prudent in self-treatment with calming and sleeping products, due to an awareness-raising campaign about the side-effects ... to the growing preference for plant-based calming and sleeping products perfectly... Euromonitor International's Calming and Sleeping in Romania report offers a comprehensive guide to the size ...
June 2015
19 pages
Calming and Sleeping in New Zealand
US$ 990.00
... , as consumers believe it is cheaper to purchase through this channel. Growth in calming and sleeping products containing magnesium also drove sales in 2014; however, the ... from 2013. Examples of products containing magnesium... Euromonitor International's Calming and Sleeping in New Zealand report offers a comprehensive guide to the size and shape of the ...
June 2015
24 pages
Calming and Sleeping in Australia
US$ 990.00
... to 2013, calming and sleeping in 2014 saw 6% current value growth, to reach AUD16 million. Growth was largely driven by the ageing population in Australia. As a person ... of menopause, are also factors contributing to less sleep each night. Euromonitor International's Calming and Sleeping in Australia report offers a comprehensive guide to the size and ...
June 2015
18 pages
Investigation Report on China Atorvastatin Market, 2010-2019
US$ 2,000.00
... in the near future. Atorvastatin, a common drug that can lower blood cholesterol levels, was developed by Pfizer under the trade name of Lipitor. Boasting of nearly ... miracle among all the medicines for sale. After entering China, atorvastatin develops fast with annual sales value rising from less ...
June 2015
30 pages
Investigation Report on China Tacrolimus Market, 2010-2019
US$ 2,000.00
... Tacrolimus (also FK506) is a macrolide lactone immunosuppressive drug discovered from a soil sample that contained the bacterium Streptomyces tsukubaensis in 1984 by Fujisawa Pharmaceutical Co., Ltd. Tacrolimus ...
June 2015
30 pages
Investigation Report on China Insulin Lispro Market, 2010-2019
US$ 2,000.00
... : market size of insulin lispro in China market share of manufacturers of Insulin Lispro in China retail price of insulin lispro in Chinese market major manufacturers of insulin lispro in Chinese market market outlook of insulin lispro in China The author suggests ...
June 2015
20 pages
Investigation Report on China Capecitabine Market, 2010-2019
US$ 2,000.00
... name of Xeloda and then spread through over 80 countries and regions in 2 years. In Mar. 2001, capecitabine entered China to be clinically used for the treatment of advanced breast cancer, colorectal cancer and other solid tumors. The chemotherapy for colorectal cancer ...
June 2015
30 pages
Investigation Report on China Celecoxib Market, 2010-2019
US$ 2,000.00
... the market. In Sep. 2000, celebrex (celecoxib capsule) made by Pfizer Inc was approved by CFDA to enter China. Celecoxib develops fast then, ... celecoxib in Chinese market market outlook of celecoxib in China The author suggests the following groups of people purchase this report: manufacturers of NSAIDs ...
June 2015
20 pages
Investigation Report on China Desloratadine Market, 2010-2019
US$ 2,000.00
... desloratadine in China market share of manufacturers of desloratadine in China price of desloratadine in Chinese market major manufacturers of desloratadine in Chinese market market outlook of desloratadine in China ...
June 2015
30 pages
Investigation Report on China Doxofylline Market, 2010-2019
US$ 2,000.00
... doxofylline in China market share of manufacturers of doxofylline in China price of doxofylline in Chinese market major manufacturers of doxofylline in Chinese market market outlook of doxofylline in China ...
June 2015
30 pages
Investigation Report on China Ezetimibe Market, 2010-2019
US$ 2,000.00
... estimate of the incidence of hyperlipemia is 7%-8% while the actual incidence might be above 10%. Over 100 million people in China have to receive ... this report: market size of ezetimibe in China price of ezetimibe in Chinese market market outlook of ezetimibe in China The author suggests the following groups ...
June 2015
20 pages
Investigation Report on China Liraglutide Market, 2011-2019
US$ 2,000.00
... diabetes incidence in China. Liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, was developed by Novo Nordisk in 2008 to treat diabetes. Liraglutide, a derivative attained by attaching a fatty acid molecule to GLP-1 molecule, can reduce the HbA1c level and weight of type 2 diabetes ...
June 2015
25 pages
Investigation Report on China Methylprednisolone Market, 2010-2019
US$ 2,000.00
... varieties of steroid’s APIs, half are made in China. As a variety performing well in hospitals in recent years, methylprednisolone, ... methylprednisolone entered China in the late 1990s under the trade names of Medrol (Pfizer) and Solu-Medrol (Pharmacia & Upjohn). The APIs and preparations of methylprednisolone ...
June 2015
30 pages
Investigation Report on China Octreotide Market, 2010-2019
US$ 2,000.00
... octreotide in China market share of manufacturers of octreotide in China price of octreotide in Chinese market major manufacturers of octreotide in Chinese market market outlook of octreotide in China ...
June 2015
30 pages
Investigation Report on China Recombinant Factor ? Market, 2010-2019
US$ 2,000.00
... and treatment of hemophilia have a huge market. Apart from Bayer Schering, Baxter and Wyeth also make recombinant factor Ⅷ too. After entering China, recombinant factor Ⅷ develops ... report: sales status of recombinant factor Ⅷ in China price of recombinant factor Ⅷ in Chinese market major manufacturers of recombinant factor Ⅷ in Chinese market share of dosage forms of recombinant factor Ⅷ in China market outlook of recombinant factor Ⅷ in China The author suggests ...
June 2015
30 pages
Calming and Sleeping in the United Arab Emirates
US$ 990.00
... became public in 2013, some 50% of the population of the United Arab Emirates suffers from poor sleep on a regular basis. The main factors behind this are ... , exposure to noise pollution and the worries... Euromonitor International's Calming and Sleeping in United Arab Emirates report offers a comprehensive guide to the size and shape of the ...
June 2015
24 pages
Calming and Sleeping in Indonesia
US$ 990.00
City dwellers in Indonesia generally face high stress levels, combined with a busy lifestyles, ... help from OTC products, driving demand for calming and sleeping in Indonesia. Euromonitor International's Calming and Sleeping in Indonesia report offers a comprehensive guide to the size and ...
June 2015
21 pages
Investigation Report on China Tiotropium Bromide Market, 2010-2019
US$ 2,000.00
... tiotropium bromide in Chinese hospitals price of tiotropium bromide in Chinese hospitals major manufacturers of tiotropium bromide in Chinese market share of different dosage forms of tiotropium bromide in Chinese hospitals market outlook of tiotropium bromide in China ...
June 2015
20 pages
Investigation Report on China Olmesartan Market, 2010-2019
US$ 2,000.00
... hypertension is a controllable disease. In 1991, olmesartan medoxomil was successfully developed by Sankyo Pharmaceuticals Co., Ltd and was patented in many countries. In Apr. 2002, olmesartan medoxomil ... ARBs, olmesartan medoxomil has distinctive pharmacokinetic properties. It develops fast after entering China ...
June 2015
20 pages
Investigation Report on China Insulin Detemir Market, 2010-2019
US$ 2,000.00
... insulin detemir in Chinese market price of insulin detemir in Chinese market major manufacturers of insulin detemir in China share of different dosage forms of insulin detemir in Chinese market market outlook of insulin detemir in China ...
June 2015
20 pages
Investigation Report on China Linezolid Market, 2010-2019
US$ 2,000.00
... Linezolid, a synthetic oxazolidinone, was developed by Pharmacia & Upjohn. In 2000, it was approved by FDA to be used for infection caused by gram-positive ... China, linezolid market has long been monopolized by foreign pharmaceutical corporations. Since the patent for linezolid ...
June 2015
20 pages
